Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | S100A4 | P26447 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18339841 | 0.80 | GPR35 (0.44) | TDP1ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL35212403 | 0.80 | ACHE (0.43) | TDP1ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL35212357 | 0.80 | GPR35 (0.44) | TDP1ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL7871363 | 0.80 | ACHE (0.43) | TDP1ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL18658368 | 0.80 | TDP1 (0.44) | TDP1ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL35212145 | 0.80 | GPR35 (0.44) | TDP1ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL1573408 | 0.80 | GPR35 (0.44) | TDP1ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL18339431 | 0.80 | GPR35 (0.44) | TDP1ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL35212373 | 0.80 | GPR35 (0.44) | TDP1ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL7220671 | 0.76 | NR4A1 (0.41) | TDP1ALDH1A1MAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005731-B2 | Modulators of the retinoid-related orphan receptor gamma (ROR-gamma) for use in the treatment of autoimmune and inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2018-06-26 | — | — | US | disclosed |
| US-10005731-B2 | Modulators of the retinoid-related orphan receptor gamma (ROR-gamma) for use in the treatment of autoimmune and inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2018-06-26 | — | — | US | disclosed |
| US-10005731-B2 | Modulators of the retinoid-related orphan receptor gamma (ROR-gamma) for use in the treatment of autoimmune and inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2018-06-26 | — | — | US | disclosed |
| EP-3219711-A1 | MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | Glaxo Group Limited (GB) | 2017-09-20 | — | — | EP | disclosed |
| EP-3219711-A1 | MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | Glaxo Group Limited (GB) | 2017-09-20 | — | — | EP | disclosed |
| EP-2928885-B1 | MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | GLAXO GROUP LTD (GB) | 2017-03-22 | — | — | EP | disclosed |
| EP-2928885-B1 | MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | GLAXO GROUP LTD (GB) | 2017-03-22 | — | — | EP | disclosed |
| CN-105121430-A | Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases | GLAXO GROUP LTD | 2015-12-02 | — | — | CN | disclosed |
| US-20150299121-A1 | MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2015-10-22 | — | — | US | disclosed |
| US-20150299121-A1 | MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2015-10-22 | — | — | US | disclosed |
| US-20100210634-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-08-19 | — | — | US | disclosed |
| US-7718657-B2 | Certain indanyl urea modulators of the cardiac sarcomere | CYTOKINETICS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718657-B2 | Certain indanyl urea modulators of the cardiac sarcomere | CYTOKINETICS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718657-B2 | Certain indanyl urea modulators of the cardiac sarcomere | CYTOKINETICS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| EP-1959962-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20070197507-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197507-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197507-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007078815-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007078815-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299121-A1 | MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | RORB, RORC, RORA | TDP1 4569/4885ALDH1A1 1045/4885MAPT 3835/4885 |
| US-20100210634-A1 | Certain Chemical Entities, Compositions and Methods | TNNI3, TNNT2, MYLK2 | TDP1 3263/4885ALDH1A1 3619/4885MAPT 900/4885 |
| US-10005731-B2 | Modulators of the retinoid-related orphan receptor gamma (ROR-gamma) for use in the treatment of autoimmune and inflammatory diseases | RORB, RORC, RORA | TDP1 4569/4885ALDH1A1 1045/4885MAPT 3835/4885 |
| US-20070197507-A1 | Certain chemical entities, compositions and methods | TNNI3, TNNT2, MYLK2 | TDP1 3263/4885ALDH1A1 3619/4885MAPT 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.